Avelox Dosage/Direction for Use

Method of administration: The film-coated tablet should be swallowed whole with sufficient liquid and may be taken independent of meals.
Dosage regimen: Dose (adults): The recommended dose for Moxifloxacin (Avelox) is 400 mg once daily (1 film-coated tablet) for the previously mentioned indications and should not be exceeded.
Duration of treatment: The duration of treatment should be determined by the severity of the indication or clinical response. The following general recommendations for the treatment of infections are made: See Table 7.

Click on icon to see table/diagram/image

The recommended duration of treatment for the indication being treated should not be exceeded.
Moxifloxacin (Avelox) 400 mg film-coated tablets has been studied in clinical trials for up to 21 days (in complicated skin and skin structure infections).
Missed Dose: If a dose is missed, it should be taken as soon as the patient remembers on the same day. Double doses should not be taken to compensate for a missed dose.
Additional information on special populations: Pediatric patients: The efficacy of Moxifloxacin (Avelox) in children and adolescents has not been established. Currently available data are described in Adverse Reactions, Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions. No recommendation on posology can be made.
The safety of Moxifloxacin (Avelox) in children below the age of 6 years has not been established. Currently available data are described in Adverse Reactions, Pharmacology: Pharmacodynamics, Pharmacokinetics and Toxicology: Preclinical safety data under Actions.
Geriatric patients: No adjustment of dosage is required in elderly.
Ethnic differences: No adjustment of dosage is required in ethnic groups.
Patients with hepatic impairment: No dosage adjustment is required in patients with impaired liver function (see "Precautions" in patients with liver cirrhosis).
Patients with renal impairment: No dose adjustment is required in patients with renal impairment (including creatinine clearance ≤ 30 mL/min/1.73 m²) and in patients on chronic dialysis i.e. hemodialysis and continuous ambulatory peritoneal dialysis.